Related Experiment Video
Updated: Oct 9, 2025
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer
Zainab Al-Taie1,2, Mark Hannink3,4, Jonathan Mitchem1,5,6
1Institute for Data Science & Informatics, University of Missouri, Columbia, MO 65211, USA.
Abstract:
Breast cancer (BC) is the leading cause of death among female patients with cancer. Patients with triple-negative breast cancer (TNBC) have the lowest survival rate. TNBC has substantial heterogeneity within the BC population. This study utilized our novel patient stratification and drug repositioning method to find subgroups of BC patients that share common genetic profiles and that may respond similarly to the recommended drugs. After further examination of the discovered patient subgroups, we identified five homogeneous druggable TNBC subgroups. A drug repositioning algorithm was then applied to find the drugs with a high potential for each subgroup. Most of the top drugs for these subgroups were chemotherapy used for various types of cancer, including BC. After analyzing the biological mechanisms targeted by these drugs, ferroptosis was the common cell death mechanism induced by the top drugs in the subgroups with neoplasm subdivision and race as clinical variables. In contrast, the antioxidative effect on cancer cells was the common targeted mechanism in the subgroup of patients with an age less than 50. Literature reviews were used to validate our findings, which could provide invaluable insights to streamline the drug repositioning process and could be further studied in a wet lab setting and in clinical trials.
Insights
Researchers identified five druggable subgroups of triple-negative breast cancer (TNBC) using a novel patient stratification and drug repositioning method. These subgroups may respond to specific therapies, with ferroptosis or antioxidative effects as key mechanisms.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Breast cancer (BC) is a leading cause of cancer death in women.
- Triple-negative breast cancer (TNBC) presents the poorest prognosis due to its heterogeneity.
- Existing treatments for TNBC are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify homogeneous, druggable TNBC subgroups using a novel patient stratification method.
- To apply drug repositioning algorithms to find potential therapies for identified TNBC subgroups.
- To elucidate the underlying therapeutic mechanisms of repositioned drugs in TNBC.
Main Methods:
- Utilized a novel patient stratification technique to group BC patients by genetic profiles.
- Employed a drug repositioning algorithm to identify high-potential drugs for TNBC subgroups.
- Analyzed biological mechanisms, including ferroptosis and antioxidative effects, targeted by identified drugs.
Main Results:
- Identified five homogeneous and druggable TNBC subgroups.
- Chemotherapy agents were frequently identified as top repositioned drugs for TNBC subgroups.
- Ferroptosis was a common mechanism for subgroups defined by neoplasm subdivision and race.
- Antioxidative effects were prominent in subgroups of patients younger than 50.
Conclusions:
- The study successfully stratified TNBC patients into distinct, druggable subgroups.
- Drug repositioning identified potential therapies targeting specific TNBC subtypes.
- Findings provide a foundation for further preclinical and clinical investigation of novel TNBC treatments.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...